Keppra 250mg Tablet contains Levetiracetam, an antiepileptic drug used primarily for the treatment of partial onset seizures, myoclonic seizures, and primary generalized tonic-clonic seizures in patients with epilepsy. Levetiracetam’s exact mechanism of action is not fully understood, but it is believed to modulate synaptic neurotransmitter release through binding to the synaptic vesicle protein SV2A, thereby inhibiting abnormal neuronal excitability. Keppra is indicated as monotherapy or adjunctive therapy in adults and children aged one month and older. The 250mg dosage is often utilized as a starting dose or for dose adjustments based on clinical response and tolerability. Keppra is generally well tolerated, with common adverse effects including somnolence, dizziness, fatigue, and behavioral changes such as irritability or mood swings. It is essential to adhere to prescribed dosing schedules and not discontinue therapy abruptly to avoid increased seizure frequency. Dose adjustments may be necessary in patients with renal impairment. Keppra has minimal drug interactions, making it a preferred choice in polytherapy regimens. Patients should be monitored regularly for efficacy and side effects, and any new or worsening symptoms should be reported to a healthcare professional promptly.